Evercore ISI Raises its Price Target on argenx (ARGX)

argenx SE (NASDAQ:ARGX) is one of the 10 Best European Growth Stocks to Buy.

On May 15, 2026, Evercore ISI analyst Gavin Clark-Gartner raised the firm’s price target on argenx SE (NASDAQ:ARGX) to $1,059 from $1,007 while maintaining an Outperform rating on the shares.

Earlier in the week, BofA analyst Tazeen Ahmad raised the firm’s price target on argenx SE (NASDAQ:ARGX) to $1,016 from $1,013 and kept a Buy rating on the shares. BofA said the recent FDA approval expanding the label for Vyvgart and Vyvgart Hytrulo in generalized myasthenia gravis broadens the addressable U.S. patient population by approximately 11,000 patients by extending treatment eligibility across all MG serotypes.

On May 8, 2026, argenx announced that the U.S. FDA approved a label expansion for Vyvgart and Vyvgart Hytrulo for the treatment of adult patients with generalized myasthenia gravis. The supplemental Biologics License Application expands the indication to include all serotypes of adult gMG patients, including anti-AChR-Ab positive, anti-MuSK-Ab positive, anti-LRP4-Ab positive, and triple seronegative patients.

argenx SE (NASDAQ:ARGX) is a commercial-stage biopharmaceutical company focused on developing therapies for autoimmune diseases globally.

While we acknowledge the risk and potential of ARGX as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and doing so within a shorter time frame. If you are looking for an AI stock that is more promising than ARGX and that has 10,000% upside potential, check out our report about this cheapest AI stock.

READ NEXT: 33 Stocks That Should Double in 3 Years and Cathie Wood 2026 Portfolio: 10 Best Stocks to Buy. 

Disclosure: None. Follow Insider Monkey on Google News.

1281292 - 11759070 - 1